Cargando…

The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model

Therapeutic regimens for chronic lymphocytic leukemia (CLL) have increasingly utilized monoclonal antibodies since the chimeric anti-CD20 antibody rituximab was introduced. Despite improved clinical outcomes, current CLL therapies are not curative. Therefore, antibodies with greater efficacy and nov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beckwith, Kyle A., Frissora, Frank W., Stefanovski, Matthew R., Towns, William H., Cheney, Carolyn, Mo, Xiaokui, Deckert, Jutta, Croce, Carlo M., Flynn, Joseph M., Andritsos, Leslie A., Jones, Jeffrey A., Maddocks, Kami J., Lozanski, Gerard, Byrd, John C., Muthusamy, Natarajan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090271/ https://www.ncbi.nlm.nih.gov/pubmed/24445867 http://dx.doi.org/10.1038/leu.2014.32

Ejemplares similares

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
por: Hicks, Stuart W., et al.
Publicado: (2017)

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
por: Stathis, Anastasios, et al.
Publicado: (2018)

Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model
por: Motiwala, Tasneem, et al.
Publicado: (2014)

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
por: Betrian, S, et al.
Publicado: (2016)

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
por: Angelova, Evgeniya, et al.
Publicado: (2019)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
por: Oostindie, Simone C., et al.
Publicado: (2019)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
por: Shah, Manisha H., et al.
Publicado: (2016)

DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
por: Oostindie, Simone C., et al.
Publicado: (2020)

Expression of IL-37 contributes to the immunosuppressive property of human CD4(+)CD25(+) regulatory T cells
por: Shuai, Xu, et al.
Publicado: (2015)

Interleukin-37 Enhances the Suppressive Activity of Naturally Occurring CD4(+)CD25(+) Regulatory T Cells
por: Wang, Da-Wei, et al.
Publicado: (2016)

The clinical features, prognostic significance, and immune heterogeneity of CD37 in diffuse gliomas
por: Yan, Xuejun, et al.
Publicado: (2021)

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
por: Stephens, Deborah M., et al.
Publicado: (2014)

The Tetraspanin Protein CD37 Regulates IgA Responses and Anti-Fungal Immunity
por: van Spriel, Annemiek B., et al.
Publicado: (2009)

Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37
por: Peeters, Rens, et al.
Publicado: (2022)

CCM no. 37
por: Serre , C
Publicado: (1978)

CD4(+) T Cell Defects in a Mulibrey Patient With Specific TRIM37 Mutations
por: Bruzzaniti, Sara, et al.
Publicado: (2020)

Solar neutrino detection by the Cl37-Ar37 method
por: Davis, R Jr, et al.
Publicado: (1965)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease
por: Hertlein, Erin, et al.
Publicado: (2013)

Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors
por: Bond, David A, et al.
Publicado: (2020)

Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells
por: Zhao, Jing-Jing, et al.
Publicado: (2014)

Anti-CD37 α-amanitin–conjugated antibodies as potential therapeutic weapons for Richter syndrome
por: Vaisitti, Tiziana, et al.
Publicado: (2022)

$\beta^{+}$ decays of $^{37}$Ca: implications for the efficiency of the $^{37}$Cl solar $\nu$ detector
por: García, A, et al.
Publicado: (1991)

37 Sonate :per chitarra
por: Paganini, Niccolo, 1782-1840
Publicado: (1987)

Geophysik 3.7
por: Rawer, Karl
Publicado: (1984)

37-May 2013
Publicado: (2013)

Aspects Operationnels 37
por: Boutheon, M
Publicado: (1978)

37. Pädiatrischer Samstag
Publicado: (2023)

Comparison of membrane proteins of Mycobacterium tuberculosis H37Rv and H37Ra strains
por: Målen, Hiwa, et al.
Publicado: (2011)

$\beta$-decay of $^{37}$Ca
por: Trinder, W, et al.
Publicado: (1994)

G protein-coupled receptor 37 (GPR37) emerges as an important modulator of adenosinergic transmission in the striatum
por: Morató, Xavier, et al.
Publicado: (2019)

CD37 high expression as a potential biomarker and association with poor outcome in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2020)

IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma
por: Elfrink, Suraya, et al.
Publicado: (2022)

P611: CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA
por: Kusowska, Aleksandra, et al.
Publicado: (2023)

N-terminal proteolytic processing of G proteiin-coupled receptor 37 (GPR37)
por: Mattila, Orvokki, et al.
Publicado: (2015)

Role of IL-37- and IL-37-Treated Dendritic Cells in Acute Coronary Syndrome
por: Zhu, Ruirui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bn0gp3dfnn5balkmo9he5j10rg